Mehmet Melikoglu1. 1. Department of Dermatalogy, Atatürk University School of Medicine, Erzurum, Turkey.
Abstract
OBJECTIVE: The main purpose of this research was to crosscheck sleep quality in patients with psoriasis with that in healthy individuals and to evaluate a possible relationship between sleep quality and disease severity in these patients. MATERIALS AND METHODS: Fifty-eight patients with plaque psoriasis and 58 age- and gender-matched healthy individuals were included. The Psoriasis Area and Severity Index (PASI) scoring method was used to assess the disease severity in patients with psoriasis. The sleep quality of the participants was evaluated by the Pittsburgh Sleep Quality Index (PSQI). The sleep quality scores of the patients with psoriasis were compared to those of healthy controls. Pearson's correlation test and independent samples t-test and were used to interpret the data. RESULTS: The mean disease duration was 11.1±7.4 years (mean±standard deviation), and the mean PASI was 14.1±5.3. In total, 60% of the patients with psoriasis (n=35) experienced poor sleep quality, and this frequency was considerably higher in the patients with psoriasis than in the healthy controls (p<0.000). Further, the mean PSQI in the patients with psoriasis (7.01±41.4) was higher than that in the healthy controls (4.18±2.76, p=0.000). The scores of daytime dysfunction, habitual sleep efficiency, and subjective sleep quality, which are the three components of sleep quality, were considerably higher in the patients with psoriasis than in the healthy controls (p=0.007, p=0.032, and p=0.034, respectively). CONCLUSION: Our results showing impaired sleep quality and its association with disease severity in patients with psoriasis may contribute to the management of psoriasis.
OBJECTIVE: The main purpose of this research was to crosscheck sleep quality in patients with psoriasis with that in healthy individuals and to evaluate a possible relationship between sleep quality and disease severity in these patients. MATERIALS AND METHODS: Fifty-eight patients with plaque psoriasis and 58 age- and gender-matched healthy individuals were included. The Psoriasis Area and Severity Index (PASI) scoring method was used to assess the disease severity in patients with psoriasis. The sleep quality of the participants was evaluated by the Pittsburgh Sleep Quality Index (PSQI). The sleep quality scores of the patients with psoriasis were compared to those of healthy controls. Pearson's correlation test and independent samples t-test and were used to interpret the data. RESULTS: The mean disease duration was 11.1±7.4 years (mean±standard deviation), and the mean PASI was 14.1±5.3. In total, 60% of the patients with psoriasis (n=35) experienced poor sleep quality, and this frequency was considerably higher in the patients with psoriasis than in the healthy controls (p<0.000). Further, the mean PSQI in the patients with psoriasis (7.01±41.4) was higher than that in the healthy controls (4.18±2.76, p=0.000). The scores of daytime dysfunction, habitual sleep efficiency, and subjective sleep quality, which are the three components of sleep quality, were considerably higher in the patients with psoriasis than in the healthy controls (p=0.007, p=0.032, and p=0.034, respectively). CONCLUSION: Our results showing impaired sleep quality and its association with disease severity in patients with psoriasis may contribute to the management of psoriasis.
Authors: B E Strober; J M Sobell; K C Duffin; Y Bao; A Guérin; H Yang; O Goldblum; M M Okun; P M Mulani Journal: Br J Dermatol Date: 2012-11-02 Impact factor: 9.302
Authors: R Zachariae; H Zachariae; K Blomqvist; S Davidsson; L Molin; C Mørk; B Sigurgeirsson Journal: Br J Dermatol Date: 2002-06 Impact factor: 9.302
Authors: Giovanni Damiani; Abdulla Watad; Charlie Bridgewood; Paolo Daniele Maria Pigatto; Alessia Pacifico; Piergiorgio Malagoli; Nicola Luigi Bragazzi; Mohammad Adawi Journal: Nutrients Date: 2019-01-27 Impact factor: 5.717
Authors: Julia Nowowiejska; Anna Baran; Marta Lewoc; Paulina Grabowska; Tomasz W Kaminski; Iwona Flisiak Journal: J Clin Med Date: 2021-02-09 Impact factor: 4.241